TY  - JOUR
AU  - Nelson, AW
AU  - Groen, AJ
AU  - Miller, JL
AU  - Warren, AY
AU  - Holmes, KA
AU  - Tarulli, GA
AU  - Tilley, WD
AU  - Katzenellenbogen, BS
AU  - Hawse, JR
AU  - Gnanapragasam, VJ
AU  - Carroll, JS
Y2  - 2020/12/21
Y1  - 2017/01/15
SN  - 0303-7207
UR  - http://hdl.handle.net/11343/257340
AB  - Estrogen Receptor-β (ERβ) has been implicated in many cancers. In prostate and breast cancer its function is controversial, but genetic studies implicate a role in cancer progression. Much of the confusion around ERβ stems from antibodies that are inadequately validated, yet have become standard tools for deciphering its role. Using an ERβ-inducible cell system we assessed commonly utilized ERβ antibodies and show that one of the most commonly used antibodies, NCL-ER-BETA, is non-specific for ERβ. Other antibodies have limited ERβ specificity or are only specific in one experimental modality. ERβ is commonly studied in MCF-7 (breast) and LNCaP (prostate) cancer cell lines, but we found no ERβ expression in either, using validated antibodies and independent mass spectrometry-based approaches. Our findings question conclusions made about ERβ using the NCL-ER-BETA antibody, or LNCaP and MCF-7 cell lines. We describe robust reagents, which detect ERβ across multiple experimental approaches and in clinical samples.
LA  - English
PB  - ELSEVIER IRELAND LTD
T1  - Comprehensive assessment of estrogen receptor beta antibodies in cancer cell line models and tissue reveals critical limitations in reagent specificity
DO  - 10.1016/j.mce.2016.11.016
IS  - Molecular and Cellular Endocrinology
VL  - 440
IS  - C
SP  - 138-150
L1  - /bitstream/handle/11343/257340/PMC5228587.pdf?sequence=1&isAllowed=y
ER  -